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Abstract
Background: The aim of our study was to analyze the effect of taxane-based chemotherapy on tumor angiogenesis in 
patients with advanced epithelial ovarian cancer.
Methods: Within a prospective phase II trial, 32 patients with stage IIIC and IV ovarian cancer were treated with either 
two or three cycles of neoadjuvant chemotherapy prior to cytoreductive surgery. Carboplatin (AUC5) and docetaxel 
(75 mg/m2) were administered intravenously in a 3-weekly schedule. Changes in intratumor microvessel density (MVD) 
were assessed with immunohistochemistry by staining pre- and posttreatment surgical tumor specimens with 
panendothelial, neovascular and lymphatic vessel markers.
Results: Mean values of MVD defined by CD31, CD34, CD105 and D2-40 antibodies showed 12.3, 21.0, 2.7 and 3.1 
vessels per high power field (HPF) before chemotherapy and increased after treatment to 15.3, 21.8, 4.8 and 3.6 per HPF, 
respectively. These changes were significant for CD31 (p = 0.04) and for CD105 (p = 0.02).
Conclusion: Taxane-based chemotherapy appears to promote tumor vascularization when administered every 3 
weeks. A possible explanation is the secondary recovery of MVD in response to immediate cytotoxic and 
antiangiogenic effects of the chemotherapy. If confirmed prospectively, these findings favor shorter treatment intervals 
of taxane-based chemotherapy to counteract proangiogenic recovery.
Background
Although about 80% of advanced ovarian cancer patients
respond well to standard management - primary cytore-
ductive surgery followed by platinum/taxane-based che-
motherapy - the majority of patients develop recurrent
disease and die of progressive disease[1]. Therefore
changes in therapeutic procedures are of clinical interest.
The application of neoadjuvant chemotherapy in
advanced ovarian cancer is the subject of past and recent
study efforts [2-4]. Results of a recently reported phase 3
study with 704 patients enrolled and a treatment schedule
with 3 cycles carboplatin/paclitaxel preoperatively dem-
onstrated that neoadjuvant chemotherapy produces simi-
lar PFS and OS rates compared to standard primary
cytoreductive surgery and provides a significantly lower
perioperative morbidity and mortality in the group
treated with neoadjuvant chemotherapy [5].
Preoperative chemotherapy provides an excellent
opportunity to analyze cytotoxic therapy effects on the
tumor microenvironment; an area of research which
received little consideration in the literature so far. Malig-
nant tumors are regarded as complex tissues in which
genetically altered malignant cells interact with several
normal cell types that collaborate and support malignant
growth [6] Based on the impact of neovascularization
which contributes to the growth of a tumor mass and the
formation of metastases, great efforts have been under-
taken to develop therapeutic tools to target this process
[7].
Intratumor microvessel density (MVD) has been used
to examine the role of vascularization within the malig-
nant process. High MVD is associated with parameters of
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tumor aggressiveness such as greater incidence of metas-
tases and decreased survival [8]. It was found to have
independent prognostic significance when compared
with traditional prognostic markers by multivariate anal-
ysis in many types of cancer. While the prognostic impact
of high MVD In ovarian cancer patients was demon-
strated in numerous retrospective studies [9-14], other
studies failed to prove a significant association [15-17].
CD31, a transmembrane glycoprotein found at the
intercellular junctions of endothelial cells and CD34, a
surface glycoprotein of unknown function serve as
panendothelial markers, whereas CD105 (endoglin) is
expressed almost exclusively on proliferating endothelial
cells that are induced by tumoral factors for neoangio-
genesis [18-20]. D2-40, a monoclonal antibody, specifi-
cally recognises podoplanin and is the most sensitive and
specific antibody for the detection of lymphatic endothe-
lium [21].
Anticancer chemotherapeutic agents are known to
directly inhibit tumor cell proliferation. In addition, che-
motherapeutic drugs were reported to have antiangio-
genic activity [22].
The aim of our study was to assess the chemotherapeu-
tic effect on angiogenesis by comparing tumor vascula-
ture before and after neoadjuvant chemotherapy in
ovarian cancer patients.
Methods
Between February 2003 through March 2008, patients
with advanced stage IIIC and IV ovarian cancer and large
volume ascites (>500 mL) were treated with neoadjuvant
chemotherapy as part of a multicenter prospective ran-
domized phase 2 trial [23]. This trial was planned to eval-
uate response to neoadjuvant chemotherapy, and to
analyze surgical outcome. Treatment consisted of either
two or three of six cycles of intravenous carboplatin (area
under the curve 5) and 75 mg/m2 of docetaxel at 21-day
intervals before cytoreductive surgery in order to find a
suitable regimen for a planned phase 3 trial. All patients
were regularly followed up at 3-month intervals for the
first two years and at 6-month intervals thereafter.
To confirm the diagnosis laparoscopic biopsy was per-
formed before chemotherapy and tumor samples were
taken from the ovary and/or the peritoneum of the
abdominal wall. Cytoreductive surgery was performed
within four weeks of the last scheduled chemotherapy
cycle and tumor tissue was excised at the beginning of
cytoreductive surgical procedures. If no macroscopic
residual tumor was detectable at the ovary and/or the
peritoneum of the abdominal wall, any macroscopic
tumor tissue was obtained irrespective of the anatomic
site.
This is a single institution analysis. Of 93 patients
enrolled in the multicenter study, 43 patients were treated
at the University of Bonn Medical Center and form the
basis of our analysis. Tissue sampling and documentation
was performed in a standardized fashion. Of the 43
patients, in 32 cases, paired tissue samples from laparos-
copy and laparotomy were assessable for the evaluation of
MVD before and after treatment.
None of the patients received erythropoetin stimulat-
ing agents before cytoreductive surgery. The protocol was
approved by the institutional review board. All patients
gave written informed consent.
Immunohistochemistry
Original hematoxylin and eosin stained slides were
reviewed by a board certified pathologist (N.F.). Corre-
sponding tumor blocks were obtained. Formalin-fixed
tissue specimens were embedded in paraffin and 2 μm
sections were dried overnight at room temperature,
deparaffinized and rehydrated by decreasing concentra-
tions of ethanol followed by incubation in Tris buffer. For
antigen retrieval, the sections were microwaved twice for
15 min at 600 W in 10 mM citrate buffer, pH 6. The fol-
lowing steps were performed semiautomatically using a
streptavidin-biotin-peroxidase technique and a DAKO
TechMate™ 500 following the instructions of the provider
(Dako, Hamburg, Germany). Positive control experi-
ments were performed using tissue slides with microves-
sels and negative controls by substituting the primary
antibody by non-specific immunoglobulin. All specimens
were stained within the same pass.
The following primary antibodies were used for immu-
nohistochemical detection: anti-human CD 31 (Clone JG
70 A, 1:100; DAKO), anti-human CD34 (Clone QBEnd-
10, 1:100; DAKO), anti CD 105 (Clone SN6 h, 1:50;
DAKO) and anti-human D2-40 (Clone D2-40, 1:50; Sig-
net, Dedham, MA, USA).
MVD was measured as reported by Weidner et al. [24].
Using a light microscope, an experienced blinded investi-
gator screened with a 40× magnification for a single area
of invasive tumor representative of the highest microves-
sel density (neovascular "hotspot"). Hotspots were
defined as the area of greatest vasculature within the
tumor epithelium and immediate adjacent stroma. Areas
of stroma without tumor cells were not considered. Ves-
sels with muscular walls were excluded. The number of
positively stained vessels was counted in 3 high power
fields (200× or 0.74 mm2) in each tissue sample and the
average value was used as a basis for calculating.
Statistical analysis
Statistical analysis was performed using the software SAS
9.1.3 (SAS Institute Inc. Cary, NC, USA) and included
non-parametric group comparison tests (Mann-Whitney
and Wilcoxon-test) nonparametric (Spearman) correla-
tion tests, and parametric (Cox proportional) and non-Pölcher et al. BMC Cancer 2010, 10:137
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parametric (Kaplan-Meier) survival analysis with p < 0.05
considered significant.
Results
The clinical and histological characteristics of the
patients included in this study are summarized in Table 1.
Ascites volume, target lesions and CA 125 serum levels
were compared to pretreatment findings before cytore-
ductive surgery. All patients responded to the initial pre-
operative treatment.
For each marker, pre- and posttreatment specimens of
32 patients were analyzed. In three cases the pretreat-
m e n t  s p e c i m e n s  s h o w e d  s e v e r e  a r t e f a c t s ,  w h i c h  p r e -
vented their use for the designated analyses due to poor
quality. Pre- and posttreatment values were excluded
pairwise in these cases.
The highest vessel counts were found by immunostain-
ing with anti-CD34 antibody. There was a strong correla-
tion between both panendothelial markers CD34 and
CD31 (Spearman-Rho correlation coefficient 0.67, signif-
icance <0.01). By comparison, the selective staining of
CD105 (neovascularisation) and D2-40 (lymphatic ves-
sels) generated clearly lower values of MVD (Figure 1).
Changes from pre- to posttreatment MVD are shown in
Figure 2. CD31 and CD105 values showed a significant
increase after treatment (p = 0.04 and p = 0.016). There
was no significant difference in the mean changes of all
MVD markers between two and three cycles of treatment
(data not shown). Changes of MVD markers (CD31,
CD34 and CD105) were not associated with grade or
residual tumor after surgery and further, changes of the
lymphatic vessel marker D2-40 were not associated with
nodal involvement, grade or residual tumor after surgery.
Mean follow up was 24 months (7 to 65 months),
median progression-free survival (PFS) was 13.3 months
(95% Confidence Interval (CI) 10.9 to 15.7) and median
overall survival (OS) was 36.0 (95% CI 15.9 to 56.0)
months. After dichotomization at the median into groups
expressing high or low levels of CD31, CD34, CD 105 and
D2-40 no significant differences were predictable in the
univariate analyses for PFS and OS in both, pretreatment
and posttreatment values. The same applies to comparing
p a t i e n t s  w i t h  i n c r e a s i n g  o r  d e c r e a s i n g  l e v e l s  o f  M V D
after therapy.
Representative images of the microvessel immunos-
tainings are shown in Figure 3.
Discussion
While chemotherapy has been reported to target
endothelial cells in blood capillaries, this study demon-
strates that taxane-based neoadjuvant chemotherapy in
ovarian cancer does not exert antiangiogenic treatment
effects in residual tumor foci.
Table 1: Patient characteristics
N
Number of patients 32
Age -- (y)
Median 60
Range 34-78
Histological type
serous/serous-papillary 31
Endometrioid 1
Histological grade
G 2 12
G 3 20
Stage
III C 30
IV 2
CA 125 (U/mL)
Median 1376
Range (86-9030)
CA 125 (U/mL) after 
preoperative treatment
Median 71
Range (17-2794)
Number of chemotherapy 
cylcles before cytoreductive 
surgery
Two 19
Three 13
Residual disease after 
cytoreductive surgery
no gross residual disease 9
≤ 1 cm 19
>1 cm 4
Lymph node status
N0* 13
N1 7
NX 12
Recurrence status (%)
recurrent disease 21
Dead 17
*at least 25 lymph nodesPölcher et al. BMC Cancer 2010, 10:137
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Although endothelial cells are assumed to be geneti-
cally stable and have a low mutation rate, antineoplastic
cytotoxic agents are regarded as inhibitors of angiogene-
sis [25]. Taxanes are microtubule-stabilizing drugs and
inhibit endothelial cell proliferation and tubule formation
in vitro [26,27]. Docetaxel, which is the study medication
of this trial, appears to be more potent at inhibiting
angiogenesis in vitro and in vivo than paclitaxel [28],
which is the standard medication for treatment of
advanced ovarian cancer patients. Furthermore, antian-
giogenic activity is not only thought to be mediated by
direct effects on endothelial cells but it is also thought to
be mediated through effects on cancer cells. Killing can-
cer cells and eliminating critical cell survival or pro-
angiogenic factors (e.g. vascular endothelial growth fac-
tor), also affects the endothelial cell compartment and
causes antiangiogenic activity [29]. Therefore, comparing
tumor samples taken before and after neoadjuvant che-
motherapy, one would expect to find a reduction of
microvessel density (MVD) in the posttreatment speci-
mens by an inhibition of tumor angiogenesis.
However, in the current analysis all vessel markers
showed increasing mean levels after treatment, indicating
a lack of a relevant antiangiogenic treatment effect.
CD105 has been considered as a specific and sensitive
marker to detect newly sprouting vessels [19]. In two-
thirds of the tumor specimens posttreatment samples
showed an increased number of CD105 positive vessels as
a sign of newly generated vessels. Lymph vessels however,
visualized by D2-40 did not show changes in the tumor
environment. An inhibitory effect of chemotherapy or,
inversely, an increase of the lymph vessel density due to a
proangiogenic effect was not found in this study.
Tumor and host-mediated pathways might inverse anti-
angiogenic treatment effects. There is a growing body of
evidence suggesting that circulating bone marrow
Figure 1 Mean values of microvessel density per high powerfield in 32 tumor samples before and after neoadjuvant chemotherapy in 
ovarian cancer patients.Pölcher et al. BMC Cancer 2010, 10:137
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Figure 2 Changes of microvessel density per high powerfield in 32 tumor samples after chemotherapy treatment. Waterfall plots for (A) 
panendothelial (CD31) and (B) selective endothelial markers (CD105); (C) joint illustration of all markers.
A 
 
 
B 
 
 
C Pölcher et al. BMC Cancer 2010, 10:137
http://www.biomedcentral.com/1471-2407/10/137
Page 6 of 8
derived endothelial progenitor cells (CEP) are able to sup-
port the vascularization of tumors and may therefore play
a synergistic role with angiogenesis [30]. Tumor vascula-
ture does not necessarily derive from endothelial cell
sprouting, but CEP home to sites of neovascularization
and differentiate into endothelial cells [31]. Recent data
demonstrates that some chemotherapeutic drugs can
cause simultaneously host-mediated counterregulatory
responses from the bone-marrow resulting in tumor
angiogenesis and vasculogenesis [32]. This mobilization
effect in CEP levels may facilitate tumor cell repopulation
during the common time intervals between the individual
chemotherapy cycles [33].
Chemotherapy is optimally given at a maximum toler-
ated dose, with off-therapy intervals of 3 weeks to rescue
bone marrow and intestine. Antiangiogenic therapy
requires that endothelial cells be exposed to steady blood
levels of the inhibitor [34]. Most recent investigations on
the antiangiogenic efficacy of different application sched-
ules suggested the use of a tightly spaced, continuous
application of appropriate anticancer chemotherapeutic
agents [35,36]. These application schedules are able to
exert a strong antiangiogenic effect as indicated by an
increase of apoptosis of tumor endothelial cells [37]. Fur-
thermore, the mobilization of CEP is decreased in these
schedules [33,38]. It has been hypothesized that a more
frequent administration of paclitaxel exhibits proapop-
totic and antiangiogenic properties and therefore
increases its antineoplastic effect [39,40].
A phase 3 trial (JGOG3016) with 637 advanced ovarian
cancer patients enrolled compared a dosedense weekly
paclitaxel regimen (Carboplatin AUC 6 q21d and Pacli-
taxel 80 mg/m2 d1, 8, 15, × 6-9) with standard treatment
(Carboplatin AUC 6 and Paclitaxel 180 mg/m2 q21 × 6-9)
after cytoreductive surgery [41]. This study demonstrated
a significant improvement of PFS in the arm with weekly
taxane (28 vs.17 months; p = 0.02) and a significant
improvement in the overall survival rate after 3-years (72
vs. 65%; p = 0.03). Increased doses of paclitaxel of 200
mg/m2, 225 mg/m2 or 250 mg/m2 given every 3 weeks
have not shown a benefit in survival rates compared to
standard dosage (175 mg/m2) [42-44]. The authors con-
cluded that higher survival rates without improved
response rates in this study might be attributed to an
additional antiangiogenic effect of the weekly application
of paclitaxel.
We are aware of several limitations in our experimental
approach. Laparoscopic biopsies are mostly smaller than
tumor specimens after cytoreductive surgery and may
have fewer vascular "hotspots". Therefore initial MVD
may be underestimated. We tried to avoid paired sam-
pling from different sites at the pre- and posttreatment
surgical procedures, but this was not always feasible due
to tumor response after neoadjuvant chemotherapy.
However, the immunohistochemistry analysis is based on
exclusively pathologically confirmed vital tumor tissue.
Therefore, significant differences in MVD derived from
different sites are possible but unlikely.
Inflammatory cells, namely monocytes, macrophages,
T lymphocytes and neutrophils, fully participate in the
angiogenic process by secreting cytokines that may affect
endothelial cell functions, including proliferation, migra-
tion and activation. Therefore, MVD might also be
affected by an immune response to tumor cell damage.
The timing of surgery after the preoperative regimen may
be crucial, at least with respect to the expression of these
MVD markers. All patients included in this study under-
went cytoreductive surgery at least after 21 days and
within 35 days after the completion of preoperative che-
motherapy. The long drug-free periods might provide
time for endothelial cells to repopulate the damaged tis-
Figure 3 Representative images of the immunostaining showing 
antigen expression in pre- and posttreatment samples of pa-
tients treated with neoadjuvant chemotherapy.Pölcher et al. BMC Cancer 2010, 10:137
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sues, thereby reducing an antiangiogenic effects of these
drugs [45].
Neither pretreatment MVD nor MVD changes after
chemotherapy examined here were associated with sur-
vival. However, the limited sample size and the inclusion
of patients with unfavorable prognostic markers (ascites,
stage IIIC and IV) decrease the ability to demonstrate any
effect on survival.
Specific antiangiogenic therapy targeting the vascular
epithelial growth factor (VEGF) - pathway has found its
way into clinical trials and first results show promise for
this approach in ovarian cancer treatment [46,47]. Many
u n a n s w e r e d  q u e s t i o n s  r e m a i n  t o  b e  c l a r i f i e d .  I t  i s  n o t
clear whether combination or concurrent antiangiogenic
therapy is more sufficient or whether maintenance treat-
ment should be pursued. Recently, converse treatment
effects were reported as antiangiogenic therapy elicited
malignant progression in animal trials [48,49].
Our data indicates that neoadjuvant chemotherapy
provides an excellent opportunity to in vivo assess
changes in the tumor environment by comparing pre-
and posttreatment samples. This may be helpful to iden-
tify treatment effects of cytotoxic drugs.
Conclusion
These findings suggest that in addition to the cytotoxic
effect, the taxane-based chemotherapy cannot exert its
antiangiogenic effect within a 3 weekly schedule. A possi-
ble explanation is the secondary recovery of MVD in
response to immediate cytotoxic and antiangiogenic
effects of taxane-based chemotherapy. If confirmed pro-
spectively, these findings favor shorter treatment inter-
vals of taxane-based chemotherapy to counteract
proangiogenic recovery.
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